NCT04637360 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004 Aug;15(8):2208-18.
Cunningham J, Locatelli F, Rodriguez M
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011 Apr;6(4):913-21. doi: 10.2215/CJN.06040710. Epub 2011 Mar 31. Review.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1-130. doi: 10.1038/ki.2009.188.
London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC
Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008 Sep;19(9):1827-35. doi: 10.1681/ASN.2007050622. Epub 2008 May 14.
Mazzaferro S, Tartaglione L, Rotondi S, Bover J, Goldsmith D, Pasquali M
News on biomarkers in CKD-MBD. Semin Nephrol. 2014 Nov;34(6):598-611. doi: 10.1016/j.semnephrol.2014.09.006.
Westin G, Björklund P, Akerström G
Molecular genetics of parathyroid disease. World J Surg. 2009 Nov;33(11):2224-33. doi: 10.1007/s00268-009-0022-6. Review.
Zheng CM, Zheng JQ, Wu CC, Lu CL, Shyu JF, Yung-Ho H, Wu MY, Chiu IJ, Wang YH, Lin YF, Lu KC
Bone loss in chronic kidney disease: Quantity or quality? Bone. 2016 Jun;87:57-70. doi: 10.1016/j.bone.2016.03.017. Epub 2016 Apr 2. Review.

To Study the Bone Turnover Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Calcium Sensing Receptor Agonist Cinacalcet Treatment

Details for clinical trial NCT04637360

Clinical trial NCT04637360 - References